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Abstract
Mouse models of hepatocellular carcinoma (HCC)
simulate specific subgroups of human HCC. We
investigated hepatocarcinogenesis in Mdr2-
knockout (Mdr2-KO) mice, a model of inflammation-
associated HCC, using gene expression profiling and
immunohistochemical analyses. Gene expression
profiling showed that although Mdr2-KO mice differ
from other published murine HCC models, they share
several important deregulated pathways and many
coordinately differentially expressed genes with human
HCC data sets. Analysis of genome positions of
differentially expressed genes in liver tumors revealed
a prolonged region of down-regulated genes on murine
chromosome 8 in three of the six analyzed tumor
samples. This region is syntenic to human chromosomal
regions that are frequently deleted in human HCC and
harbor multiple tumor suppressor genes. Real-time
reverse transcription-PCR analysis of 16 tumor
samples confirmed down-regulation of several tumor
suppressors in most tumors. We show that in the
aged Mdr2-KO mice, cyclin D1 nuclear level is increased
in dysplastic hepatocytes that do not form nodules;
however, it is decreased in most dysplastic nodules
and in liver tumors. We found that this decrease is
mostly at the protein, rather than the mRNA, level.
These findings raise the question on the role of
cyclin D1 at early stages of hepatocarcinogenesis in
the Mdr2-KO HCC model. Furthermore, we show
that most liver tumors in Mdr2-KO mice were
characterized by the absence of B-catenin activation.
In conclusion, the Mdr2-KO mouse may serve as a
model for B-catenin–negative subgroup of human
HCCs characterized by low nuclear cyclin D1 levels in
tumor cells and by down-regulation of multiple tumor
suppressor genes. (Mol Cancer Res 2007;5(11):1159–70)
Introduction
Human hepatocellular carcinoma (HCC) is one of the major
health care burdens, the molecular pathogenesis of which is still
not well understood. Mouse models of HCC have been widely
used to study the molecular mechanisms of the disease and to
test new therapeutic approaches. Comparison of global expres-
sion patterns of orthologous genes in human and murine HCCs
showed that certain mouse HCC models closely reproduce spe-
cific subgroups of human HCCs (1, 2). Mdr2-knockout (Mdr2-
KO) mice represent a model of inflammation-associated HCC
(3). They lack the liver-specific P-glycoprotein responsible for
phosphatidylcholine transport across the bile canalicular mem-
brane. The absence of phospholipids from bile results in bile
regurgitation into the portal tracts (4), causing portal inflam-
mation and fibrosis that mimic human progressive familial
intrahepatic cholestasis (5). Liver inflammation and toxicity
induced by bile salts in Mdr2-KO mice lead to the development
of hepatocyte dysplasia, and by 16 months of age, virtually
100% of Mdr2-KO mice show liver tumors. It was previously
found that both tumor necrosis factor a and nuclear factor nB
are elevated in inflamed portal tracts of Mdr2-KO mice, and
that reduction of tumor necrosis factor-a levels or nuclear fac-
tor nB inactivation prevented tumor development, providing a
rational link between inflammation and tumorigenesis in this
HCC model (6).
We have recently shown that the precancerous stages of liver
disease in the Mdr2-KO mice are characterized by induction of
many oncogenes, on one hand, and by multiple protective mech-
anisms, including up-regulation of many anti-inflammatory and
antioxidant genes, on the other hand (7). We have also revealed
an age-dependent progressive deregulation of genes that con-
trol lipid metabolism; this effect is probably responsible for the
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Mol Cancer Res 2007;5(11). November 2007 1159frequent appearance of steatotic dysplastic nodules in the livers
of Mdr2-KO mice at 12 months of age. Here, we continue our
study on the molecular mechanisms of hepatocarcinogenesis in
Mdr2-KO mice by characterizing the cancerous stage of liver
disease in this HCC model. We compare the results of the global
gene expression profiling of tumorous and nontumorous liver
tissues from Mdr2-KO mice at 16 months of age with other
published data on global expression profiling of mouse HCC
models and human HCC samples (1). We determine the dynamic
changes in Mdr2-KO livers between mice at 12 and 16 monthsof
age and the essential differences between tumorous, nontu-
morous, and control liver tissues of Mdr2-KO mice at 16 months
of age. The most important microarray findings were confirmed
by real-time reverse transcription-PCR (RT-PCR) and by immu-
nohistochemistry on the expanded set of Mdr2-KO liver tumors.
We show that the Mdr2-KO HCC model shares many dere-
gulated HCC-associated genes and pathways with human HCC
and is more similar to human HCC cases characterized by better
survival (8). We show that Mdr2-KO tumors are characterized
by down-regulation of transcripts of multiple tumor suppressor
genes and by the absence of h-catenin activation. We also show
an intriguing pattern of nuclear staining of cyclin D1in hepa-
tocytes, which raises a question about the roleof this well-known
oncogene in hepatocarcinogenesis in the Mdr2-KO HCC model.
Results
Liver Tumor Development
We have previously described that livers of Mdr2-KO mice
at 12 months of age were characterized by disrupted lobular
structure and appearance of dysplastic nodules, some of them
being steatotic (7). The number and size of visible liver tumors
in Mdr2-KO mice increased gradually with age. At 16 months
of age, almost all Mdr2-KO mice had at least one tumor with
a diameter of at least 0.5 cm. In rare cases, tumors could also be
found in mice between the ages of 9 and 12 months.
The number of steatotic degenerated hepatocytes also in-
creased with age, and a significant proportion of tumors were
steatotic as well. We have analyzed 21tumor tissue samples
from 10 Mdr2-KO males at 16 months of age: for 11 tumors,
both formalin-fixed and frozen tissue samples were analyzed;
for additional 5 tumors, only formalin-fixed tissue samples
were accessible; and for another 5 tumor samples, only frozen
tissue samples were accessible (Table 1). Most tumors were
well-differentiated HCC as determined by their aberrant growth
patterns (thick trabeculae, acinar, and solid growth) and absence
of portal tracts. Hepatocyte variability in nuclear size was
similar to that in surrounding nontumorous liver tissue. Some
tumors were also classified as moderately differentiated HCC,
based on predominantly trabecular and solid growth patterns,
prominent nucleoli observed in >50% of hepatocytes, and
marked hepatocyte pleomorphism compared with surrounding
nontumorous liver tissue. Number of mitoses observed in
tumors varied from 5 to 56 per 50 high-power fields (Table 1).
Common Characterization of Gene Expression in Tumors
The liver RNA samples from six Mdr2-KO tumors, six
nontumorous liver tissues (four matched and two unmatched),
and three control heterozygous mice at 16 months of age were
subjected to gene expression profiling using the genome-scale
Affymetrix Mouse Genome 430 2.0 Array. Cluster analysis
(9, 10) of the expression profiling data revealed increased
heterogeneity of samples as follows: tumorous > nontumorous
> heterozygous controls (Fig. 1). This analysis enabled sepa-
ration of heterozygous samples from Mdr2-KO nontumorous
tissues in the space of all the involved genes (these two groups
form two fairly distinct clusters). On the other hand, the tumors
exhibited high variability and differed from each other. A sim-
ilar separation of tumor samples was obtained using the clus-
ters of genes with tendency to down-regulation in tumors
(Supplementary Fig. S1). These gene clusters separated tumors
from both nontumorous tissues and the heterozygous controls.
The clustering results were in accord with the results of
supervised analysis (Fig. 2) showing that (a) genes down-
regulated in tumors were more statistically significant for
separating tumors from nontumorous liver samples than genes
up-regulated in tumors, and (b) most genes differentially ex-
pressed between nontumorous tissues and heterozygous con-
trols were also differentially expressed between tumors and
heterozygous controls, but not vice versa.
Functional Analysis of Differentially Expressed Genes
A substantial fraction of genes differentially expressed
in nontumorous tissues of Mdr2-KO mice, when compared
with Mdr2-heterozygotes at age 16 months (Supplementary
Table S1), was also differentially expressed in Mdr2-KO tissues
when compared with Mdr2-heterozygotes at 3 and 12 months
of age (7). The common fraction of genes up-regulated both at
12 and 16 months of age was enriched with ‘‘cell adhesion’’,
‘‘cell communication’’, and ‘‘defense response’’ genes and
contained many potential oncogenes discussed previously (7).
The functional study of differentially expressed genes in 16-
month-old mice using pathway-oriented and Gene Ontology
enrichment analyses revealed progressive down-regulation
of liver-specific genes in tumors and Mdr2-KO nontumorous
liver tissues compared with heterozygous controls. The most
significantly enriched fractions among genes up-regulated in
tumors compared with heterozygous tissues were genes related
to such Gene Ontology biological processes as ‘‘cell prolifer-
ation’’, ‘‘cytoskeleton organization and biogenesis’’, and ‘‘cell
adhesion’’. The latter category was also the most enriched
among the genes up-regulated in Mdr2-KO nontumorous tis-
sues compared with heterozygotes. Remarkably, the majority of
the discovered cell cycle–related genes up-regulated in tumor-
ous and nontumorous Mdr2-KO samples compared with hete-
rozygous controls were involved in the advanced stages of
mitosis. Several transcriptional targets of h-catenin, including
specific markers of its activation (11, 12), were down-regulated
in most Mdr2-KO tumors. Analysis of the known transcrip-
tional targets of other oncogenic pathways showed no
convincing evidence of activation in Mdr2-KO tumors of
p53, Rb, or Myc regulatory pathways. Several genes that were
previously shown to correlate with p53 staining in human HCC
(13) were coordinately differentially regulated between tumor
samples and heterozygotes in some Mdr2-KO tumor samples.
However, immunohistochemical staining of 16 tested Mdr2-KO
liver tumors (listed in Table 1) with anti-p53 antibody did not
reveal p53 accumulation in any of them (not shown).
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Chromosomal aberrations are frequent in liver cancer (14)
and can be a reason for the variability of gene expression pro-
files in tumors. Recently, it was shown that an approximate
evaluation of DNA ploidity of large chromosomal regions
may be deduced from the gene expression profile based on the
suggestion that a deleted (or an amplified) region has a ten-
dency to decrease (or increase) the average expression levels
FIGURE 1. Two-dimensional clustering of gene expression data. The Mdr2-KO data set had been preprocessed by filtering of the valid Affymetrix probes
with a SD filter. The 7,167 probes possessing SD for log 2 transformedvalues higher then 0.3 in all samples were submittedto SPC algorithm incorporate d
into CTWC tool. The samples include six Mdr2-KO tumorous samples (marked T), six Mdr2-KO nontumorous samples (marked N), andthree heterozygous
control samples (marked H). A. The color-coded expression matrix with aligned dendrograms of samples (left) andgenes ( above). The height of
dendrogram branches represents the sensitivity variable (temperature) in SPC clustering algorithm. B. The color-coded matrix of the standardized Euclidean
distances between the analyzed samples. The order of samples in A and B is identical.
TABLE 1. Characterization of Liver Tumors of 16-Month-Old Mdr2-KO Mice
Tumor
No.
Tumor
Diameter (cm)
Tumor
Grade
Mitoses
per 50 HPF
Gene Expression Relative to the Matched Nontumorous Liver Tissue*
Cyclin D1Cdh1 Cdkn1 b Dleu2 Lats1 Mxi1 Plagl1 Rbl2 Ubd
49T1 >1.3 Wellc 5 Down Down
84T1 >1.3 Well 7 Down Down Down Down
85T1b 0.5-0.7 Well/mod. 4
85T2c 0.5-0.7 Down Down
85T3c 0.5-0.7
93T1 1.1-1.3 Well 18 Down Down
93T2c 0.5-0.7 Down Down Up
94T1b 0.5-0.7 Well 7
96T1 >1.3 Well 9
96T2c 0.5-0.7 Down Down Down Up
704T1b 0.5-0.7 Well/mod. 56
704T2b 0.5-0.7 Well/mod. 25
704T3b 0.5-0.7 Well 19
705T1>1 .3 Mod. 5 Down Down Down Down Down Up
705T2 1.1-1.3 Mod. 15 Down Down Down Down Down Down Up
706T1>1 .3 Well 6 Down Down Down Up
706T2 1.1-1.3 Well 25 Up
706T3 0.8-1.0 Well 10
707T1>1 .3 Well 36 Down Down Down Up
707T2 0.8-1.0 Well 6
707T3c 0.5-0.7 Down Down Down Down Down Up
NOTE: Tumors that were analyzed by gene expression profiling are shown in boldface.
Abbreviation: HPF, high-power field (200).
*Results of the real-time RT-PCR. Only genes down-regulated or up-regulated at least 2-fold are shown.
cTumors represented by frozen samples only.
bTumors represented by histologic samples only.
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1161(15). Analysis of genome position–specific deviations of aver-
age gene expression in our data revealed multiple areas of
up-regulation and down-regulation in tumor samples, including
the longest common region of down-regulation, which was
localized on chromosome 8 (Fig. 3) and found in three of the
six tested tumors. Calculation of the approximate boundaries of
this down-regulated (‘‘presumed deleted’’) region enabled us to
map its syntenic regions in the human genome. The presumed
deleted region in mice was syntenic to human chromosomal
areas known to be frequently deleted in HCC: 4q2, 8p2, 16q1,
and 16q2 (14, 16). These regions, both in mice and in humans,
contain several genes whose loss of heterozygosity, mutations,
or down-regulation was shown to be associated with HCC and
other types of cancer: Pdgfrl (17, 18), Vps37a (19), Wwox (20),
Cdh1 (21), Rbl2 (22), and Cbfa2t3 (23). We confirmed reduc-
tion of copy numbers of the chromosomal region containing the
Cdh1 gene (or its loss) in all three tumor samples for which this
deletion was presumed by semiquantitative PCR (Supplemen-
tary Fig. S2).
Comparison with Published Data
Gene expression patterns of tumorous and nontumorous
liver tissue samples of Md2-KO mice were compared with
those of previously published murine HCC models. For this
purpose, the Affymetrix expression data set of the Mdr2-KO
model was converted into a format comparable to that of two-
color spotted arrays (see Materials and Methods). Hierarchical
cluster analysis of the joint data set containing data of Mdr2-
KO and other murine HCC models, filtered by variance criteria,
enabled separation of all murine HCC models into three large
clusters: cluster A, similar to human HCC with ‘‘poor
survival’’; cluster B, similar to human HCC with ‘‘better
survival’’; and a cluster having limited relevance to human
HCC, in full accordance with previously published results (1).
Cluster B comprised E2f1, Myc, and Myc/E2f1 models, as well
as the Mdr2-KO subcluster (Fig. 4).
Ordering the samples belonging to both cluster A and cluster
B, according to their similarity in the space of the 500 most
variable genes with the help of the SPIN application (24),
resulted in a marginal position of Myc/transforming growth
factor a and DENA model samples (cluster A) and disper-
sion of most Mdr2-KO samples among the samples of cluster B
(Supplementary Fig. S3). Remarkably, Mdr2-KO samples
were ordered in a way that could be related to tumor prog-
ression: the nontumorous samples were the most distant from
the cluster A end, and the two samples expressing a-feto pro-
tein, M55T and M56T, were interspersed with the marginal
cluster A samples.
Analysis of the distances between average expression
profiles of different models showed the proximity of Mdr2-
KO samples to E2F1and Myc/E2f1models (Supplementary
Fig. S4A). The similarity with the E2F1model was higher for
Mdr2-KO nontumorous tissues samples, mostly on account of a
relatively low number of differentially expressed genes
obtained from both of these models. There was no significant
up-regulation of E2F1-induced genes in the Mdr2-KO model.
The Acox1model also shared substantial similarity to Mdr2-
KO tumors.
The Mdr2-KO gene expression data set was also compared
with published human HCC data set (8). In full agreement with
the above-mentioned results of comparison with murine HCC
models (1), again we see that Mdr2-KO samples (both tumorous
and nontumorous) are more similar to human HCC samples
with better survival (cluster B in Fig. 4B and Supplementary
FIGURE 2. The supervisedanalysis of d ifferential expression. A. Number of genes differentially expressed by 2-fold between the experimental groups
depicted at X-axis. Data for the 2-foldchanges in expression average of log 2–transformedvalues andfor the 2-foldchanges that were also significant in
ANOVA statistical test are shown with gray andblack columns, respectively. B and C. Venn diagrams showing the cross sections between the gene groups:
2-foldchanges ( B); 2-foldchanges statistically valid atedby ANOVA test ( C). T, tumorous; N, nontumorous; H, heterozygous liver RNA samples.
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1162Fig. S4B) than to human samples with poor survival (cluster A
in Fig. 4B). The set of genes that were down-regulated in Mdr2-
KO tumorous versus nontumorous samples, and also in the
human HCC versus normal samples, was enriched with
metabolic genes, especially the genes involved in the metabo-
lism of amino acids. The common set of up-regulated genes was
enriched with genes classified as ‘‘cell cycle,’’ ‘‘cell adhesion,’’
and ‘‘extracellular matrix’’ genes.
A significant number of HCC-associated genes were found
to be coordinately deregulated in Mdr2-KO mice and in
published human HCC data sets (Supplementary Table S1). The
most prominent among them being up-regulated—Axl, Cbr3,
Cd36, Lgals1, Lgals3, Jun, and Ubd; down-regulated—Ahcy,
Cbs, Gnmt (three genes encoding enzymes that control S-
adenosylmethionine catabolism), C6, C8a, C8b (encoding com-
plement components), and cytochrome P450 genes Cyp1a2,
Cyp2e1, Cyp4v3, Cyp8b1 (8, 25-29). Overexpression of the
Ubd protein may cause chromosomal instability (30). We con-
firmed the up-regulation of its transcript in Mdr2-KO livers by
real-time RT-PCR: Ubd was highly up-regulated in non-
tumorous liver tissues (6- to 23-fold compared with Mdr2-
heterozygotes) and progressively up-regulated in most tumors
(Table 1and Supplementary Tables S2 and S3).
Down-Regulation of mRNA Level of Multiple Tumor
Suppressor Genes in Tumorous Tissues of Mdr2-KO
Mice
Gene expression profiling revealed down-regulation of
multiple tumor suppressor genes in the tumorous tissues of
Mdr2-KO mice compared with their matched nontumorous
samples. Twenty-six genes annotated as ‘‘tumor suppressors’’
were down-regulated in at least one of the six tested tumorous
RNA samples; 12 among them were down-regulated in at least
two tumors and 8 were down-regulated in at least three tumors.
We carried out real-time RT-PCR analysis of seven genes from
the latter set on 16 tumorous RNA samples, including those 6
samples subjected to gene expression profiling. This analysis
revealed that four genes (Cdh1, Dleu2, Plagl1, and Rbl2)
were down-regulated each in at least 6 tumors (Table 1). Genes
Cdh1 and Rbl2 were mapped inside the presumed deleted region
on murine chromosome 8 (discussed above). Among the 16
tested tumors, 11 had down-regulation of at least two tumor
FIGURE 3. Chromosomal po-
sition-associatedchanges in
gene expression profiles in chro-
mosome 8. A. The color-coded
matrix of differential expression
of 306 relevant chromosome
8 genes (details in Materials
and Methods) between all Mdr2-
KO samples andtheir heterozy-
gous controls. The genes are
ordered according to their posi-
tion in chromosome 8. B. The
smoothenedd ifferential expres-
sion of genes in chromosome
8 plottedagainst their chromo-
somal positions. The smoothened
differential expression was calcu-
latedas d ifferential expression of
neighboring genes between
tumors andmatchednontumo-
rous liver tissues of Mdr2-KO
mice (for details, see Materials
andMethod s).
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1163suppressor genes, 7 had down-regulation of at least three tumor
suppressor genes, and 4 tumors had down-regulation of at least
four tumor suppressor genes. Only 5 tumors exhibited no down-
regulation of any of the seven tested tumor suppressor genes.
Cyclin D1 Nuclear Level Is Decreased in Hepatocytes of
Tumors and Most Dysplastic Nodules in Mdr2-KO Mice
We have previously shown that during the precancerous
stage, cyclin D1is overexpressed in the livers of Mdr2-KO
mice both at the mRNA (Affymetrix array) and protein
(Western blot) levels (7). In the current work, we studied the
cellular and cytoplasmic or nuclear localization of cyclin D1by
immunohistochemistry. High levels of nuclear cyclin D1were
found in hepatocytes of Mdr2-KO in all lobular zones during
the precancerous stage at all tested ages: 3, 6, 9, and 12 months
(data for 3 and 12 months of age are presented in Fig. 5A).
In the appropriate heterozygous controls, nuclear cyclin D1
staining has been observed only in a small fraction of
hepatocytes in zone 2 (Fig. 5A, bottom row). The strongest
nuclear cyclin D1staining has been found in dysplastic
hepatocytes that do not produce nodules, both in the cases of
large-cell and small-cell dysplasia. After 9 months of age,
dysplastic nodules appeared in the livers of Mdr2-KO mice.
Most of these nodules were characterized by a significant
decrease of nuclear cyclin D1level in hepatocytes (Fig. 5B).
Similarly, a significant decrease of nuclear cyclin D1level
was observed in all tested liver carcinomas of Mdr2-KO mice
(more than 30 tumors in more than 20 animals were screened;
typical example is shown in Fig. 5C). Average inclusion of
bromodeoxyuridine (BrdUrd) in liver tumors was f3-fold
FIGURE 4. The combined clustering of gene expression data of the Mdr2-KO model with data of other murine models (A) andhuman HCC expression
data (B). The Mdr2-KO expression data were preprocessed as described in Materials and Methods and submitted to coclustering with published murine and
human expression data sets in the space of SD filtered genes with valid expression values in both compared data sets. Black, cluster A (poorer survival);
white, cluster B (better survival); striped, cluster C (limited relevance to human HCC); gray, Mdr2-KO.
Katzenellenbogen et al.
Mol Cancer Res 2007;5(11). November 2007
1164higher than that in matched nontumorous regions (Fig. 5C and
D), and the number of BrdUrd-positive hepatocytes directly
correlated with the number of cyclin D1–negative hepatocyte
nuclei (Fig. 5D), showing a higher proliferation rate of tumors
with decreased nuclear cyclin D1level. Global gene expression
profiling revealed that cyclin D1mRNA levels in nontumorous
tissues of Mdr2-KO mice were f4-fold higher than those in
heterozygous controls, and remained high, although variable,
in most tumorous samples. Only in one sample, D93T1, the
cyclin D1mRNA level was down-regulated compared with the
matched nontumorous sample. Real-time RT-PCR of 16
tumorous RNA samples (including 6 that were subjected to
Affymetrix arrays) showed down-regulation of cyclin D1
mRNA level in four samples only (Table 1). Thus, down-
regulation of cyclin D1in most liver tumors of Mdr2-KO mice
takes place at the protein, rather than the mRNA, level.
Activation of the Wnt signaling is known to induce cyclin
D1expression. Gene expression profiling of six HCC tumors
revealed a tendency toward down-regulation of the Wnt sig-
naling in most of these tumors (see above). To confirm these
findings and to test a correlation between cyclin D1and h-
catenin localization, we carried out h-catenin immunohisto-
chemistry. All tested HCC tumors of Mdr2-KO mice at 16
months of age were characterized by decreased membranous
staining and absence of cytoplasmic or nuclear h-catenin stain-
ing. Rare foci with high cytoplasmic h-catenin level and scat-
tered hepatocytes with high nuclear h-catenin level were found
preferentially in nontumorous liver regions (Supplementary
Fig. S5, top row). Overall, there was no correlation between
nuclear cyclin D1level and nuclear or cytoplasmic h-catenin
level; in some cases, an inverse correlation was observed (Sup-
plementary Fig. S5). Immunohistochemistry of E-cadherin in
16-month-old Mdr2-KO mice confirmed its expression profiling
data obtained by microarrays: increased expression in non-
tumorous tissues and decreased expression in most tumors
(Supplementary Fig. S6). Whereas Mdr2-heterozygous mice
preserved the typical periportal pattern of E-cadherin expression
(Supplementary Fig. S6, top row; ref. 31), in nontumorous liver
tissues of Mdr2-KO mice, E-cadherin was highly expressed in
zones 1and 2, and sometimes even in zone 3 (Supplementary
Fig. S6, middle row). In tumors, however, its expression pattern
was more heterogeneous: mostly decreased (Supplementary
Fig. S6, bottom row) but well expressed in 5 of 16 tested tumors,
similarly to human HCCs (21). Overall, there was no correlation
between E-cadherin and h-catenin levels and localization.
In human cancer, an oncogenic alternatively spliced isoform
of cyclin D1was identified (32, 33). In the sequence of the
intron 4 of the murine cyclin D1 gene, we found a translation
termination signal followed by a polyadenylate signal, similar
to the human cyclin D1 gene. However, we could not detect an
alternatively spliced cyclin D1isoform in either tumorous or
nontumorous liver tissues of Mdr2-KO mice using RT-PCR
with primers flanking the region of the suggested alternative
splicing (not shown).
Discussion
Gene expression profiling of liver tissue samples of aged
Mdr2-KO mice revealed many features that this HCC model
shares with previously published human and mouse HCC
data. About 20% of genes differentially expressed in liver
tumors of Mdr2-KO mice were also reported to be coordi-
nately differentially expressed in human HCCs (Supplementary
Table S1). The genes down-regulated in tumors were enriched
with liver-specific genes, whereas genes up-regulated in tumors
were enriched with cell cycle–related genes (especially, the
genes specific for advanced mitotic stages), similarly with pub-
lished human HCC data (13, 34). Remarkably, many tumor
suppressor genes were down-regulated in three or more of the
six tumors that were subjected to the whole genome expression
profiling (compared with their matched nontumorous tissues).
Real-time RT-PCR analysis of the expression of seven tumor
suppressor genes in an expanded tumor set showed down-
regulation of at least two tumor suppressors in 10 of the 16
tested tumors. Transcripts of genes Cdh1, Dleu2, Plagl1,
and Rbl2 were down-regulated each in at least 6 tumors
(Table 1). These data emphasize the critical importance of
down-regulation of multiple tumor suppressor genes for the
switch from nontumorous to tumorous liver tissues.
We analyzed p53 and h-catenin signaling pathways, which
are frequently deregulated in HCC. No consistent pattern of
differential regulation of p53 transcriptional targets was
revealed in Mdr2-KO tumors. Although several genes that
were previously shown to correlate with p53 immunostaining in
human HCC (13) were also coordinately differentially regulated
between tumor samples and heterozygotes in some Mdr2-KO
tumor samples, p53 accumulation in Mdr2-KO tumors could
not be detected by immunohistochemistry. However, p53
activity can be decreased not only due to mutations in the
p53 gene but also due to decreased stability of the p53 protein
or interference from other proteins with its function. Thus, it
was recently shown that the PTTG1protein is frequently
overexpressed in human HCC and interferes with the ability of
p53 to induce apoptosis (35). In the Mdr2-KO microarray data
set, the PTTG1transcript was overexpressed >2-fold in five of
the six tested liver tumors (Supplementary Table S1). Further
studies are required to reveal the role of the p53 pathway in
Mdr2-KO–induced hepatocarcinogenesis. We observed that
most transcriptional markers of h-catenin activation were
down-regulated in the majority of Mdr2-KO tumor samples.
Immunohistochemical analysis revealed no cytoplasmic or
nuclear h-catenin staining, as well as decreased membranous
staining, in all 16 tested Mdr2-KO liver tumor samples.
Nontumorous liver regions of the Mdr2-KO mice were
characterized by strongly expanded expression pattern of
membranous E-cadherin, which is strictly periportal in normal
liver (31). Such expression pattern makes it tempting to
speculate that the overexpressed E-cadherin titrates h-catenin
at the plasma membrane, thus decreasing its cytoplasmic and
nuclear pools. However, no correlation was found between loss
of E-cadherin expression and nuclear accumulation of h-catenin
either in human HCCs (21) or in other murine HCC models
(36). Similarly, in liver tumors of Mdr2-KO mice, there was no
correlation between E-cadherin expression level and cytoplas-
mic or nuclear h-catenin level.
Recently, it was shown that human and murine HCC sam-
ples could be divided into two groups that are characterized
by either h-catenin activation or genomic instability (37). Based
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suggested the presence of a prolonged deletion on chromosome
8 in three of the six tested tumor samples. Deletions in chro-
mosome 8 had already been described in mouse HCC models
(38). The presumed deletion in murine chromosome 8 is syn-
tenic to human chromosomal regions, which are frequently
deleted in human HCC and contain several tumor suppressor
genes. We confirmed deletion of the chromosomal region con-
taining the Cdh1 gene, which encodes E-cadherin, in all three
presumed liver tumor samples by semiquantitative PCR. One
of the possible candidates connecting the escape from mitotic
arrest with chromosomal instability is the Ubd (Fat10) gene,
which was highly up-regulated in all nontumorous and in most
tumorous Mdr2-KO liver samples (Table 1and Supplementary
Tables S2 and S3). Up-regulation of the Ubd expression was
reported in human HCC (39) but not in previously published
murine HCC models. Ubd was shown to bind a spindle check-
point protein, Mad2l1(which was also up-regulated in Mdr2-
KO tumor samples at mRNA level), at the time of mitosis,
resulting in increased mitotic nondisjunction and chromosomal
instability (30).
We found that genes Gnmt, Ahcy, and Cbs encoding three
subsequent steps in catabolism of S-adenosylmethionine
were all down-regulated in the six Mdr2-KO tumors analyzed
by microarrays (Supplementary Table S1). In most of these
tumors, the balance between the two forms of the methionine
adenosyltransferase enzyme, which synthesizes S-adenosylme-
thionine, was disturbed: Mat1a, specific for adult liver, was
down-regulated, whereas Mat2a, usually present in fetal liver,
was up-regulated (data not shown). Similar changes in expres-
sion of these genes were found in human HCC cases (25, 40).
Remarkably, genes Mat1a and Ahcy were also down-regulated
in the livers of Mdr2-KO mice late in the precancerous stage, at
12 month of age (f2-fold in comparison with age-matched
Mdr2-heterozygotes). Such disturbances in the metabolism of
S-adenosylmethionine, a universal donor of methyl groups,
may cause changes in the methylation pattern of DNA and
histones affecting expression pattern of multiple genes (41).
It was previously shown that based on gene expression
profiles, mouse HCC models may be divided into two groups:
more similar and less similar to human HCC cases (1). Using
the cross-platform and cross-species analyses, we showed that
(a) the Mdr2-KO model coclusterizes with mouse HCC models
that are more similar to human HCCs, and (b) most Mdr2-KO
liver samples were more similar to the better-survival human
HCC samples and better-survival–like mouse models (1).
Among the existing murine HCC models, the Mdr2-KO mice
are most similar to the E2F1-transgenic model. However, the
common differentially expressed genes of Mdr2-KO and E2F1-
transgenic mice were not enriched with E2F1transcriptional
targets. Both Mdr2-KO and E2F1-transgenic mice are charac-
terized by progressive steatosis. In E2F1-transgenic mice, the
transcription factor Srebp1(Srebf1 ) was recently identified as a
candidate responsible for induction of lipogenic enzymes (42).
However, most analyzed liver tumors of Mdr2-KO mice did not
show a consistent pattern of up-regulation of Srebp1target
genes, as was the case in tumors of E2F1-transgenic mice.
Despite the difference in molecular mechanisms that determine
the hepatocarcinogenesis in these two HCC models, they both
show that liver steatosis is an important risk factor for liver
cancer, similarly to what is known for human HCC (43).
We have recently shown that in the livers of Mdr2-KO mice,
cyclin D1, a known oncogene, is overexpressed both at the
mRNA and protein levels in the early and late precancerous
stages (7). In the current study, we show that at the cancerous
stage of liver disease, the nuclear level of cyclin D1is increased
in dysplastic hepatocytes that do not form discrete nodules but
is decreased in most dysplastic nodules, especially in well-
differentiated HCC. This expression pattern is independent
of animal age (mice at ages 12, 14, 16, and 18 months were
tested), which raises a question about the role of cyclin D1at
different stages of hepatocarcinogenesis in Mdr2-KO mice.
Cyclin D1is overexpressed at relatively early stages of dif-
ferent human tumors; in many cancers including HCC, its
overexpression is associated with poor prognosis (44). In
human HCC, the cyclin D1level compared with surrounding
nontumorous tissue correlated with tumor grade: mostly not
overexpressed in well-differentiated HCC and progressively
up-regulated in moderately and poorly differentiated HCC
(45-47). Ultrasonography and subsequent immunohistoche-
mical analyses of small human HCC nodules showed that
FIGURE 5. Nuclear level of cyclin D1 in hepatocytes of Mdr2-KO mice
revealedby immunostaining. A. Increasednuclear level of cyclin D1 in
Mdr2-KO mice (top row) comparedwith control heterozygotes ( bottom
row) both at age 3 mo (left column) and12 mo ( right column).
Magnification, 100. B. Decrease of nuclear cyclin D1 level in
hepatocytes of dysplastic nodules in Mdr2-KO mice at age 12 mo (left
column) and16 mo ( right column). Magnification, 40 (top row) and 200
(bottom row).
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hyperechoic HCCs but in 38% of hypoechoic HCCs (mainly in
moderately differentiated tumors; ref. 48). Down-regulation of
cyclin D1in some human HCC types has also been reported
(34, 49, 50). Thus, down-regulation of nuclear cyclin D1level
in dysplastic nodules and in well-differentiated HCC in the
livers of Mdr2-KO mice modulates its expression in some
subgroups of human HCC, particularly in hyperechoic liver
tumors, which are predominantly steatotic (48), as well as in
many liver tumors of Mdr2-KO mice. What could be the role of
this down-regulation in hepatocarcinogenesis? High levels of
cyclin D1in the cell nucleus during the S phase inhibit DNA
synthesis; efficient cell proliferation requires glycogen synthase
kinase 3hdependent phosphorylation of cyclin D1following
its export from the nucleus and subsequent degradation (51).
However, the oncogenic alternatively spliced isoform of cyclin
D1lacks the phosphorylation site and remains nuclear (32),
showing that at some stage, cancer cells can overcome the
inhibition of DNA synthesis by cyclin D1. Remarkably, it was
recently shown that in human esophageal adenocarcinoma,
the appearance of this alternatively spliced cyclin D1isoform
was associated with increased genomic instability (52). Pre-
viously, it was shown that cyclin D1overexpression induces
centrosome and mitotic spindle abnormalities, as well as aneu-
ploidy in murine hepatocytes in vivo and in human breast
epithelial cells in vitro (53). These findings reveal another
potential oncogenic mechanism of prolonged nuclear accumu-
lation of cyclin D1, which takes place in hepatocytes of Mdr2-
KO mice.
We hypothesize that cyclin D1plays different roles at dif-
ferent stages of hepatocarcinogenesis in Mdr2-KO mice. At the
precancerous stage, overexpression of cyclin D1in hepatocyte
nuclei engenders a tumor suppressor activity by inhibiting
DNA replication in most hepatocytes. Simultaneously, it may
FIGURE 5 Continued. C. Increased
BrdUrd inclusion and decreased nuclear
cyclin D1 level in hepatocytes of a typical
HCC nodule in a 16-mo-old Mdr2-KO
mouse. Top row, H&E staining; middle row,
cyclin D1 staining; bottom row, BrdUrd
staining. Magnification, 40, 100, and
200 (left to right). D. Graph showing a
direct correlation between the numbers of
BrdUrd-positive and cyclin D1–negative
hepatocyte nuclei. Pictures of the typical
tumorous andtheir matchednontumorous
regions of five livers from five 16-mo-old
Mdr2-KO mice were taken at the same
magnification (100), andthe percent of
BrdUrd-positive and cyclin D1–negative
hepatocytes was determined for each im-
age on a computer (an average of 364
hepatocytes were countedper each image).
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hepatocytes. The above-mentioned overexpression of the Ubd
gene should induce aneuploidy as well. In dysplastic nodules
and well-differentiated HCC, some mechanism (e.g., down-
regulation of the retinoblastoma protein; ref. 54) may cause
degradation of the cyclin D1protein, thus allowing uncon-
trolled hepatocyte proliferation. At the later stages of
moderately and poorly differentiated HCC, tumor cells may
acquire an ability to bypass the inhibitory effect of cyclin D1
on DNA synthesis. At these stages, cyclin D1is frequently
overexpressed and acts as an oncogene, stimulating increased
cell proliferation. Indeed, whereas most tested liver tumors in
Mdr2-KO mice were well differentiated, some of them
contained foci of less differentiated, ‘‘primitive’’ hepatocytes,
which had strong nuclear cyclin D1staining (data not shown).
Expression of cyclin D1is regulated by multiple factors
both at mRNA and protein levels (Fig. 6). Both in human and
mouse HCC, activation and/or mutations of h-catenin are
significantly associated with cyclin D1overexpression. Anal-
ysis of h-catenin transcriptional targets revealed absence of
activation of the classic Wnt-pathway in most HCC tumors
of Mdr2-KO mice. Both in tumorous and nontumorous liver
tissues, levels of cyclin D1mRNA did not correlate with
expression patterns of h-catenin targets, and nuclear level of
cyclin D1protein in hepatocytes did not correlate with nuclear
or cytoplasmic level of h-catenin. Thus, in the Mdr2-KO liver,
cyclin D1is up-regulated not due to activation of h-catenin.
Further studies are required to reveal the factors that regulate
cyclin D1expression in Mdr2-KO hepatocytes and the role of
cyclin D1in Mdr2-KO–induced hepatocarcinogenesis.
In conclusion, we show that the Mdr2-KO mouse may be
used as a model for human HCCs that are characterized by the
absence of h-catenin activation, by low nuclear cyclin D1levels
in tumor hepatocytes, and by down-regulation of multiple
tumor suppressor genes. The role of processes such as inflam-
mation and steatosis in hepatocarcinogenesis and of HCC-
associated regulatory proteins such as nuclear factor nB (6),
cyclin D1, E-cadherin, Ubd and proteins, which regulate
methylation, can be studied in this HCC model.
Materials and Methods
Animal Experiments
Founders of the FVB.129P2-Abcb4
tm1Bor (Mdr2-KO; old
name FVB.129P2-Pgy24
tm1Bor) and the wild-type FVB/NJ
mice were purchased from The Jackson Laboratory. Colonies of
both strains were maintained under specific pathogen-free
conditions at the Animal Facility of The Hebrew University
Medical School. The F1 hybrids produced by breeding of
an FVB.129P2-Abcb4
tm1Bor male and an FVB/NJ female were
used as age-matched controls. Harvesting of mouse liver tissues
and blood analysis for levels of liver enzymes were done as
described previously (7). BrdUrd (100 mg/kg; Sigma) was
injected i.p. twice: 4 and 2 h before liver resection. All animals
received humane care and were kept in a specific pathogen-free
facility according to the guidelines established by the U.S.
National Academy of Sciences and published by the NIH.
Gene Expression Profiling
Total RNAwas isolated from frozen liver tissues with Trizol
reagent (Invitrogen) as described by the manufacturer and sub-
jected to genome-scale gene expression profiling using Mouse
Genome Array 430A (Affymetrix, Inc.). The gene expression
values were extracted using the MAS 5.0 software and, after
thresholding and filtering procedures, were submitted to fold
change and cluster analyses (see Supplementary Methods for
details). The expression data are accessible on the GEO site,
represented according to the MIAME requirements.
Comparison with Published Data Sets
The Affymetrix expression data for the Mdr2-KO model
were presented as data on gene differential expression (in the
format of the output of two-color spotted arrays) by calculating
the log ratio of the expression values in Mdr2-KO samples to the
average of Mdr2-KO heterozygous controls. The joint data sets
containing our data and the data of other research groups were
created and analyzed as described in Supplementary Methods.
Chromosomal Analysis
Smoothened fold change values have been calculated for all
annotated genes that were relevant for position-specific fold
change analysis and plotted against their chromosomal
positions (see Supplementary Methods for details).
Real-time RT-PCR
Reverse transcription of total RNA was done using the
Moloney murine leukemia virus reverse transcriptase enzyme
and random hexamer primers from Promega. Real-time PCR
was run in triplicates using the TaqMan Universal PCR Master
Mix, primers and probe sets, and the ABI PRISM 7700
Sequence Detector system from Applied Biosystems. Threshold
cycle numbers (Ct) were determined with Sequence Detector
Software (version 1.6; Applied Biosystems) and transformed
FIGURE 6. Positive andnegative regulations of the cyclin D1
expression level. The scheme shows the main activators andinhibitors
of cyclin D1 expression (both at mRNA andprotein levels). For activating
transcription factor 3 (ATF3), both activatory andinhibitory effects on
cyclin D1 expression were reported. NFnB, nuclear factor nB; STATs,
signal transducers and activators of transcription; ETS2, erythroblastosis
virus oncogene homologue 2; CREB, cyclic AMP–responsive element
binding protein; PPARg, peroxisome proliferator–activatedreceptor g;
GSK-3h, glycogen synthase kinase 3h; PTEN, phosphatase andtensin
homologue; BTG2, B-cell translocation gene 2; Rb, retinoblastoma; Egr1,
early growth response 1.
Katzenellenbogen et al.
Mol Cancer Res 2007;5(11). November 2007
1168using the DCt method as described by the manufacturer. The
relative quantification values for each gene were normalized
against the endogenous ‘‘housekeeping’’ gene Arl6ip1, which
was one of the most uniformly expressed genes in all RNA
samples subjected to global gene expression profiling.
Immunohistochemistry
Immunostaining was done on 4-Am-thick formalin-fixed
paraffin-embedded liver tissue sections by standard proce-
dures. Antigen retrieval was done with citrate buffer (pH 6.0;
h-catenin, p53, and BrdUrd), Tris-EGTA buffer (pH 9.0;
E-cadherin), or glycine buffer (pH 9.0; cyclin D1) in a micro-
wave by boiling (BrdUrd) or using a pressure cooker (cyclin
D1, h-catenin, E-cadherin, and p53). Primary antibodies were
cyclin D1(RMAB003; Diagnostic Biosystems), h-catenin
(clone 14; BD Biosciences), E-cadherin (24E10; Cell Signaling
Technology, Inc.), p53 (CM5p; Vision Biosystems/Novocastra),
and BrdUrd (Mo744; DAKO). Secondary antibodies were from
DAKO or Zymed. Staining was developed with diaminobenzi-
dine using a kit from Zymed (cyclin D1, E-cadherin, p53, and
h-catenin) or with 3-amino-9-ethylcarbazole (BrdUrd) using a
kit from DAKO.
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